Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状被引量：3

Related studies on Aflibercept for wet AMD and macular edema

下载PDF

导出

摘要 Aflibercept是一种可溶性诱导受体,可结合血管内皮生长因子-A和胎盘生长因子,从而阻止同源血管内皮生长因子受体的结合和激活,抑制视网膜血管增生,导致新生血管退化。作为眼科一种新的抗血管生成物,其药代动力学、安全性和耐受性等获得了临床研究依据,目前主要用于湿性年龄相关性黄斑变性和黄斑水肿的治疗,现将Aflibercept在湿性年龄相关性黄斑变性和黄斑水肿治疗中的相关研究作一综述。 Aflibercept is a soluble induced receptor, which can be combined with vascular endothelial growth factor-A and placental growth factor to block the binding and activation of these homologous vascular endothelial growth factor receptor. It also inhibits retinal angiogenesis and leads to degradation of the new blood vessels. As a new anti-vascular drug in ophthalmology,Aflibercept had been gained clinical basis of pharmacokinetics, safety and tolerability, used for the treatment of wet age-related macular degeneration and macular edema. This article reviews the related studies on AfIibercept for wet age-related macular degeneration and macular edema.

作者肖昂周琼

机构地区南昌大学研究生院医学部第一临床南昌大学第一附属医院眼科

出处《眼科新进展》 CAS 北大核心 2014年第6期598-600,共3页 Recent Advances in Ophthalmology

关键词 AFLIBERCEPT 湿性年龄相关性黄斑变性黄斑水肿 Aflibercept wet age-related macular degeneration macular edema

分类号 R774.5 [医药卫生—眼科]

引文网络
相关文献

参考文献39

1Bressler NM, Bressler SB. Preventative ophthalmology. Age-related macular degeneration [J]. Ophthalmology, 1995,102 ( 8 ) : 1206-1211.
2Rahmani B ,Tielsch JM,Katz J. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey [J]. Ophthalmology, 1995,103 ( 11 ) : 1721 - 1725.
3Anderson OA,Bainbridge JW, Shima DT. Delivery of anti-angio- genic molecular therapies for retinal disease [ J ]. Drug Discov Today, 2010, 15 ( 7-8 ) : 272-282.
4Shibuya M. Angiogenesis regulated by VEGF and its receptors and its clinical application [ J 1. Rinsho Ketsueki, 2009,50 ( 5 ) : 404-412.
5Adamis AP. Pathological Retinal Angiogenesis [ M ]//Immunology, Inflammation And Disease Of The Eye. Amsterdam: Elserler Ltd,2010:280-289.
6Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration[ J]. Curr Drug Targets,2011,12(2) :173-181.
7Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for re- fractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration [ J ]. Retina,2007,27 (4) :445-450.
8Saishin Y, Takahashi K, Limae SR. VEGF-TRAP ( R1R2 ) suppres- ses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier [ J ]. J Cell Physiol, 2003,195 ( 2 ) : 241-248.
9Do DV. Retinal Pharmacotherapy, CHAPTER 37 - Fusion proteins: VEGF-Trap [M]. Edinburgh, W. B. Saunders, 2010: 259-264.
10陈丹,樊映川,李丽英.抗VEGF药物治疗新生血管性眼病的研究进展[J].国际眼科杂志,2008,8(1):123-125. 被引量：11

二级参考文献20

1周洪伟,吴强.血管内皮生长因子及其受体与眼底新生血管[J].国际眼科杂志,2007,7(3):791-795. 被引量：17
2Gragoudas ES,Adamis AP,Cunningham ET.Pegaptanib for neovascular age-related macular degeneration.N Engl J Med 2004;351:2805-2816
3Brown GC,Brown MM,Brown HC,et al.A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.Ophthalmology 2007;114(6):1170-1178
4Adamis AP,Altaweel M,Bressler NM,et al.Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.Ophthalmology 2007;114(3):615-616
5Cunningham ET,Adamis AP,Altaweel M,et al.A phase Ⅱ randomized double-masked trail of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema.Ophthalmology 2005;112(10):1747-1757
6Sun Y,Jain A,Moshfeghi DM.Elevated vascular endothelial growth factor levels in Coats disease:rapid response to pegaptanib sodium.Graefes Arch Clin Exp Ophthalmol 2007;245(9):1387-1388
7Presta LG,Chen H,O'Connor SJ,et al.Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res 1997;57:4593-4599
8Rosenfeld PJ,Brown DM,Heier JS,et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med 2006;355(14):1419-1431
9Fung AE,Lalwani GA,Rosenfeld PJ,et al.An optical coherence tomography-guided,variable dosing regimen with intravitreal ranibizumab(Lucentis)for neovascular age-related macular degeneration.Am J Ophthalmol 2007;143(4):566-583
10Rosenfeld PJ,Heier JS,Hantsbarger G,et al.Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.Ophthalmology 2006;113(4):632.e1